In summary, our studies suggest that reduced hepatic GH action in obese subjects with NASH has detrimental effects on glucose tolerance by diminishing hepatic insulin signaling and increasing hepatic glucose output. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.